Zepbound News

Latest Articles

• Why GLP-1 Medications Fail for 20% of Users: Research Suggests Combination Therapy as a Potential Solution

  Published: May 1, 2026

  Section: Fitness & Exercise

  While GLP-1 receptor agonists like Wegovy and Zepbound have revolutionized weight management, a significant subset of users—as many as one in five—experience suboptimal results. Ne...

• A Potential Catalyst in Eli Lilly’s 150-Year History

  Published: Apr 18, 2026

  Section: Companies & Industry

  Eli Lilly, a titan in the pharmaceutical industry for a century and a half, is navigating a pivotal moment with the recent launch of Foundayo, an oral GLP-1 treatment. The company,...

• Food Giants and Restaurants Pivot Menus as GLP-1 Adoption Reshapes American Caloric Consumption Patterns

  Published: Apr 2, 2026

  Section: Companies & Industry

  The rapid rise of GLP-1 weight-loss medications is forcing a structural shift in the food and beverage industry, with one in eight U.S. adults now utilizing these treatments. Major...

• FDA Grants Approval for High-Dose Wegovy as Novo Nordisk Battles Eli Lilly for Weight-Loss Dominance

  Published: Apr 2, 2026

  Section: Science & Tech

  The Food and Drug Administration has approved a 7.2-milligram dose of Novo Nordisk’s weight-loss injection, Wegovy, aimed at closing the efficacy gap with rival medications. Clinic...

• New Study Identifies Tirzepatide as Most Effective GLP-1 for Weight Loss

  Published: Mar 3, 2026

  Section: Healthy Lifestyle

  In a definitive head-to-head comparison published in JAMA Internal Medicine in late 2024, researchers have identified tirzepatide—the active ingredient in Mounjaro and Zepbound—as...

• Pharmaceutical Leaders Pivot Toward Oral Weight Loss Solutions in $100 Billion Market

  Published: Feb 17, 2026

  Section: Medical News

  Global pharmaceutical giants, including Novo Nordisk and Eli Lilly, are aggressively developing oral alternatives to blockbuster injectable weight-loss drugs. These pills aim to re...